Cabozantinib side effects: what 47,753 FDA adverse event reports show
Drug class
Kinase inhibitor
Brand names
Cabometyx
Who reports
47,753 reports · 44% serious · 5,351 with death outcome · 30% female
Used for
CABOMETYX is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC). ( 1.1 ) patients with advanced renal cell carcinoma, as a first-line treatment in combination with nivolumab ( 1.1 ) patients with hepatoc.
What it is
CABOMETYX is the ( S )-malate salt of cabozantinib, a kinase inhibitor. Cabozantinib ( S )-malate is described chemically as N -(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)- N' -(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2 S )-hydroxybutanedioate.
Boxed warning
None in the current label
Causality screen of the 40 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,089 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Scrotal dermatitis | 13 | 112.4 61.1–206.8ROR 112.4 · calibrated p 5e-7 ✓ | 79.3 EB05 49.3 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | – | not reported in cached trials |
| Palmar-plantar erythrodysaesthesia syndrome | 3,113 | 67.4 64.9–69.9ROR 72.0 · calibrated p 1e-6 ✓ | 58.4 EB05 56.7 · IC025 +5.8 3/3 methods agree | Not in label — unassessed | serious PRR 45.8 | NCT01605227: 3/681 (0.4%) on Cabozantinib (serious AE) |
| Renal cell carcinoma recurrent | 15 | 66.2 38.4–113.9ROR 66.2 · calibrated p 9e-6 ✓ | 53.8 EB05 34.6 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=15 | not reported in cached trials |
| Renal cell carcinoma | 506 | 50.1 45.7–54.9ROR 50.7 · calibrated p 1e-5 ✓ | 44.9 EB05 41.8 · IC025 +5.3 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious n=506 · 94% clinician | NCT03937219: 13/426 (3.1%) on Cabozantinib; 15/423 (3.5%) control (serious AE) |
| Thyroid hormones increased | 107 | 49.6 40.6–60.6ROR 49.7 · calibrated p 2e-5 ✓ | 44.3 EB05 37.7 · IC025 +4.9 3/3 methods agree | Lab value / disease marker | serious n=32 · 89% consumer | not reported in cached trials |
| Taste disorder | 1,992 | 48.4 46.3–50.7ROR 50.5 · calibrated p 1e-5 ✓ | 43.6 EB05 42.0 · IC025 +5.4 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 34.6 · 77% consumer | not reported in cached trials |
| Thyroid hormones decreased | 72 | 43.6 34.3–55.6ROR 43.7 · calibrated p 4e-5 ✓ | 39.4 EB05 32.3 · IC025 +4.6 3/3 methods agree | Lab value / disease marker | serious n=22 · 100% consumer | not reported in cached trials |
| Hyperkeratosis | 464 | 40.1 36.5–44.1ROR 40.5 · calibrated p 5e-5 ✓ | 36.8 EB05 34.0 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious n=106 · 85% consumer | not reported in cached trials |
| Renal cancer recurrent | 12 | 38.7 21.4–69.9ROR 38.7 · calibrated p 2e-4 ✓ | 33.9 EB05 20.6 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=8 | not reported in cached trials |
| Scrotal erythema | 12 | 34.1 19.0–61.4ROR 34.1 · calibrated p 4e-4 ✓ | 30.3 EB05 18.4 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | – | not reported in cached trials |
| Renal cancer metastatic | 56 | 33.9 25.8–44.5ROR 33.9 · calibrated p 2e-4 ✓ | 31.2 EB05 24.9 · IC025 +4.2 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious n=55 | not reported in cached trials |
| Genital blister | 19 | 32.5 20.4–51.7ROR 32.5 · calibrated p 4e-4 ✓ | 29.5 EB05 19.9 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | – | not reported in cached trials |
| Metastases to pancreas | 30 | 31.8 21.9–46.0ROR 31.8 · calibrated p 3e-4 ✓ | 29.2 EB05 21.4 · IC025 +3.7 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=28 | not reported in cached trials |
| Nasal ulcer | 101 | 29.5 24.1–36.1ROR 29.6 · calibrated p 3e-4 ✓ | 27.5 EB05 23.3 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=23 · 100% consumer | not reported in cached trials |
| Alpha 1 foetoprotein increased | 40 | 26.0 18.9–35.8ROR 26.0 · calibrated p 7e-4 ✓ | 24.3 EB05 18.6 · IC025 +3.7 3/3 methods agree | Lab value / disease marker | serious n=20 | not reported in cached trials |
| Tongue discomfort | 227 | 25.0 21.9–28.6ROR 25.1 · calibrated p 7e-4 ✓ | 23.6 EB05 21.2 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=50 · 92% consumer | not reported in cached trials |
| Hair colour changes | 669 | 24.6 22.8–26.6ROR 25.0 · calibrated p 7e-4 ✓ | 23.3 EB05 21.9 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=127 · 72% consumer | not reported in cached trials |
| Oral pain | 1,191 | 24.5 23.2–26.0ROR 25.1 · calibrated p 7e-4 ✓ | 23.3 EB05 22.2 · IC025 +4.4 3/3 methods agree | Labeled (related wording) related wording | serious PRR 12.1 · 87% consumer | not reported in cached trials |
| Genital rash | 75 | 24.4 19.4–30.8ROR 24.5 · calibrated p 9e-4 ✓ | 23.1 EB05 19.0 · IC025 +4.0 3/3 methods agree | Labeled adverse reaction exact term | serious n=12 · 79% consumer | not reported in cached trials |
| Glossitis | 187 | 24.3 21.0–28.2ROR 24.4 · calibrated p 8e-4 ✓ | 23.0 EB05 20.4 · IC025 +4.2 3/3 methods agree | Labeled adverse reaction exact term | serious n=44 · 85% consumer | not reported in cached trials |
| Metastatic renal cell carcinoma | 96 | 23.9 19.5–29.4ROR 24.0 · calibrated p 9e-4 ✓ | 22.6 EB05 19.1 · IC025 +4.0 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious n=94 | NCT03937219: 2/423 (0.5%) control (serious AE) |
| Tumour pain | 68 | 23.7 18.6–30.3ROR 23.8 · calibrated p 0.001 ✓ | 22.4 EB05 18.3 · IC025 +3.9 3/3 methods agree | Labeled (related wording) related wording | serious n=42 | NCT01605227: 1/681 (0.1%) on Cabozantinib (serious AE) |
| Cancer pain | 129 | 23.2 19.4–27.7ROR 23.2 · calibrated p 0.001 ✓ | 22.0 EB05 19.0 · IC025 +4.1 3/3 methods agree | Labeled (related wording) related wording | serious n=88 | NCT01605227: 1/681 (0.1%) on Cabozantinib (serious AE) |
| Stomatitis (mouth sores) | 2,898 | 22.0 21.2–22.8ROR 23.3 · calibrated p 9e-4 ✓ | 21.0 EB05 20.3 · IC025 +4.3 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 13.6 · 74% consumer | NCT01605227: 1/342 (0.3%) on Cabozantinib (serious AE) |
| Scrotal ulcer | 12 | 20.8 11.7–37.2ROR 20.8 · calibrated p 0.004 ✓ | 19.0 EB05 11.0 · IC025 +2.5 3/3 methods agree | Not in label — unassessed | – | not reported in cached trials |
| Hand-foot-and-mouth disease | 36 | 20.5 14.7–28.7ROR 20.5 · calibrated p 0.002 ✓ | 19.4 EB05 14.6 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=7 · ♀ 53% (drug 30%) · 78% consumer | not reported in cached trials |
| Skin ulcer | 1,135 | 20.1 19.0–21.4ROR 20.6 · calibrated p 0.002 ✓ | 19.3 EB05 18.4 · IC025 +4.2 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 7.6 · 85% consumer | NCT01605227: 2/681 (0.3%) on Cabozantinib (serious AE) |
| Tongue erythema | 35 | 19.7 14.1–27.7ROR 19.7 · calibrated p 0.003 ✓ | 18.7 EB05 14.0 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=16 · ♀ 51% (drug 30%) · 80% consumer | not reported in cached trials |
| Product selection error | 47 | 19.5 14.6–26.1ROR 19.5 · calibrated p 0.003 ✓ | 18.6 EB05 14.5 · IC025 +3.5 3/3 methods agree | Reporting / coding artifact | 100% clinician | not reported in cached trials |
| Tongue ulceration | 131 | 17.6 14.8–21.0ROR 17.7 · calibrated p 0.004 ✓ | 16.9 EB05 14.6 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=39 · 93% consumer | not reported in cached trials |
| Metastases to abdominal cavity | 19 | 17.5 11.1–27.7ROR 17.5 · calibrated p 0.006 ✓ | 16.4 EB05 10.7 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=17 | not reported in cached trials |
| Blister | 2,097 | 17.0 16.3–17.8ROR 17.8 · calibrated p 0.003 ✓ | 16.4 EB05 15.8 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious PRR 6.1 · 88% consumer | not reported in cached trials |
| Diverticulitis intestinal perforated | 12 | 16.7 9.4–29.7ROR 16.7 · calibrated p 0.008 ✓ | 15.0 EB05 8.2 · IC025 +2.3 3/3 methods agree | Not in label — unassessed | serious n=12 | not reported in cached trials |
| Genital erythema | 18 | 16.6 10.4–26.6ROR 16.6 · calibrated p 0.007 ✓ | 15.4 EB05 9.9 · IC025 +2.7 3/3 methods agree | Labeled (related wording) related wording | – | not reported in cached trials |
| Plicated tongue | 17 | 16.4 10.1–26.7ROR 16.4 · calibrated p 0.007 ✓ | 15.2 EB05 9.5 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | – | not reported in cached trials |
| Clear cell renal cell carcinoma | 24 | 15.9 10.6–23.9ROR 15.9 · calibrated p 0.007 ✓ | 15.0 EB05 10.3 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=24 · 100% clinician | NCT03937219: 2/426 (0.5%) on Cabozantinib (serious AE) |
| Hepatocellular carcinoma | 266 | 15.8 14.0–17.9ROR 15.9 · calibrated p 0.006 ✓ | 15.3 EB05 13.8 · IC025 +3.7 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious PRR 20.0 · 98% clinician | not reported in cached trials |
| Malignant neoplasm progression | 3,419 | 15.2 14.7–15.7ROR 16.3 · calibrated p 0.005 ✓ | 14.7 EB05 14.3 · IC025 +3.8 3/3 methods agree | Reporting / coding artifact | serious PRR 15.4 | NCT01605227: 1/681 (0.1%) on Cabozantinib (serious AE) |
| Pharyngeal ulceration | 44 | 15.0 11.1–20.3ROR 15.0 · calibrated p 0.008 ✓ | 14.3 EB05 11.0 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=16 · 82% consumer | not reported in cached trials |
| Immune-mediated hepatic disorder | 62 | 14.7 11.4–18.9ROR 14.7 · calibrated p 0.009 ✓ | 14.1 EB05 11.3 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=62 · 100% clinician | not reported in cached trials |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Cabozantinib as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (9 of 40 signal terms matched).
- NCT01605227 — Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Pr (N=1028, PHASE3; 395 AE terms posted; arms: Cabozantinib; Prednisone)
- NCT03937219 — Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advan (N=855, PHASE3; 410 AE terms posted; arms: Cabozantinib + Nivolumab + Ipilimumab; Placebo + Nivolumab + Ipilimumab)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Diarrhoea (diarrhea) | 9,449 | 6.5 6.4–6.7ROR 7.9 · calibrated p 0.069 | 6.4 EB05 6.3 · IC025 +2.7 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 5.4 · 71% consumer | NCT01605227: 10/681 (1.5%) on Cabozantinib (serious AE) |
| Fatigue (tiredness) | 7,696 | 4.4 4.3–4.5ROR 5.0 · calibrated p 0.231 | 4.3 EB05 4.3 · IC025 +2.1 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 3.5 · 81% consumer | NCT01605227: 20/681 (2.9%) on Cabozantinib (serious AE) |
| Off label use (used outside approved label) | 6,886 | 3.5 3.4–3.6ROR 3.9 · calibrated p 0.392 | 3.5 EB05 3.4 · IC025 +1.8 3/3 methods agree | Reporting / coding artifact | serious PRR 2.6 | not reported in cached trials |
| Nausea | 4,989 | 2.8 2.7–2.9ROR 3.0 · calibrated p 0.627 | 2.8 EB05 2.7 · IC025 +1.4 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 2.5 · 77% consumer | NCT01605227: 23/681 (3.4%) on Cabozantinib (serious AE) |
| Decreased appetite (loss of appetite) | 4,620 | 8.9 8.7–9.2ROR 9.8 · calibrated p 0.035 ✓ | 8.8 EB05 8.5 · IC025 +3.1 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 7.0 | NCT01605227: 15/681 (2.2%) on Cabozantinib (serious AE) |
| Malignant neoplasm progression | 3,419 | 15.2 14.7–15.7ROR 16.3 · calibrated p 0.005 ✓ | 14.7 EB05 14.3 · IC025 +3.8 3/3 methods agree | Reporting / coding artifact | serious PRR 15.4 | NCT01605227: 1/681 (0.1%) on Cabozantinib (serious AE) |
| Blood pressure increased | 3,196 | 9.3 9.0–9.7ROR 9.9 · calibrated p 0.033 ✓ | 9.2 EB05 8.9 · IC025 +3.1 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 5.5 · 87% consumer | not reported in cached trials |
| Palmar-plantar erythrodysaesthesia syndrome | 3,113 | 67.4 64.9–69.9ROR 72.0 · calibrated p 1e-6 ✓ | 58.4 EB05 56.7 · IC025 +5.8 3/3 methods agree | Not in label — unassessed | serious PRR 45.8 | NCT01605227: 3/681 (0.4%) on Cabozantinib (serious AE) |
| Weight decreased (weight loss) | 3,038 | 4.8 4.7–5.0ROR 5.1 · calibrated p 0.226 | 4.8 EB05 4.6 · IC025 +2.2 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 3.8 · 78% consumer | NCT01605227: 237/681 (34.8%) on Cabozantinib |
| Death | 2,908 | 1.5 1.4–1.5ROR 1.5 · calibrated p 0.652 | 1.5 EB05 1.4 · IC025 +0.5 | Outcome field, not a reaction | serious PRR 1.9 | NCT01605227: 4/681 (0.6%) on Cabozantinib (serious AE) |
| Stomatitis (mouth sores) | 2,898 | 22.0 21.2–22.8ROR 23.3 · calibrated p 9e-4 ✓ | 21.0 EB05 20.3 · IC025 +4.3 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 13.6 · 74% consumer | NCT01605227: 1/342 (0.3%) on Cabozantinib (serious AE) |
| Constipation | 2,377 | 4.9 4.7–5.1ROR 5.1 · calibrated p 0.227 | 4.8 EB05 4.7 · IC025 +2.2 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 4.2 · 83% consumer | NCT01605227: 12/681 (1.8%) on Cabozantinib (serious AE) |
| Vomiting | 2,226 | 2.1 2.0–2.2ROR 2.1 · calibrated p 0.980 | 2.1 EB05 2.0 · IC025 +1.0 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 1.9 · 72% consumer | NCT01605227: 28/681 (4.1%) on Cabozantinib (serious AE) |
| Asthenia (weakness) | 2,148 | 2.5 2.4–2.6ROR 2.6 · calibrated p 0.777 | 2.5 EB05 2.4 · IC025 +1.3 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 2.2 | NCT01605227: 18/681 (2.6%) on Cabozantinib (serious AE) |
| Blister | 2,097 | 17.0 16.3–17.8ROR 17.8 · calibrated p 0.003 ✓ | 16.4 EB05 15.8 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious PRR 6.1 · 88% consumer | not reported in cached trials |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Palmar-plantar erythrodysaesthesia syndrome — n=3,113, PRR 67.4 (also seen in trial arm)
- Hyperkeratosis — n=464, PRR 40.1
- Nasal ulcer — n=101, PRR 29.5
- Tongue discomfort — n=227, PRR 25.0
- Hair colour changes — n=669, PRR 24.6
- Hand-foot-and-mouth disease — n=36, PRR 20.5
- Tongue erythema — n=35, PRR 19.7
- Tongue ulceration — n=131, PRR 17.6
- Blister — n=2,097, PRR 17.0
- Clear cell renal cell carcinoma — n=24, PRR 15.9 (also seen in trial arm)
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Cabozantinib?
In FDA FAERS, the most frequently co-reported reaction terms for Cabozantinib are diarrhoea, fatigue, nausea, decreased appetite, blood pressure increased, palmar-plantar erythrodysaesthesia syndrome. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Cabozantinib have an FDA boxed warning?
No. The FDA label retrieved for Cabozantinib has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Cabozantinib causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 3850cce2-6137-42e5-a792-d318c4a4b3b5, effective 20251019; matched on
openfda.generic_name.exact:"CABOZANTINIB") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,129 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
CABOZANTINIB, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.